Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Relapse · Participants with Crohn's disease in remission
Usual care showed no clear difference in relapse at 12 or 24 months compared with immunosuppressive withdrawal after combination therapy (low certainty).
1 finding from 1 review
Adverse events · Participants with Crohn's disease in remission
Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after combination therapy (low certainty).
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after combination therapy (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether cannabis cigarettes (115 mg THC) changes proportion of patients achieving clinical remission compared with placebo cigarettes (very low certainty).
1 finding from 1 review
CRP (mg/dL) at end of study · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with active Crohn's disease
It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes serious adverse events compared with placebo oil (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of patients achieving clinical response · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CRP (mg/dL) at end of study · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Short‐Form 36 health survey (SF‐36) · Patients with active Crohn's disease
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of patients achieving clinical response · Patients with active Crohn's disease
It is very uncertain whether cannabis cigarettes (115 mg THC) changes proportion of patients achieving clinical response compared with placebo cigarettes (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CRP (mg/dL) at end of study · Patients with active Crohn's disease
Cannabis cigarettes (115 mg THC) showed no clear difference in CRP (mg/dL) at end of study compared with placebo cigarettes (low certainty).
1 finding from 1 review